Guidelines for the management of vitiligo: the European Dermatology Forum consensus

Br J Dermatol. 2013 Jan;168(1):5-19. doi: 10.1111/j.1365-2133.2012.11197.x. Epub 2012 Nov 2.


The aetiopathogenic mechanisms of vitiligo are still poorly understood, and this has held back progress in diagnosis and treatment. Up until now, treatment guidelines have existed at national levels, but no common European viewpoint has emerged. This guideline for the treatment of segmental and nonsegmental vitiligo has been developed by the members of the Vitiligo European Task Force and other colleagues. It summarizes evidence-based and expert-based recommendations (S1 level).

Publication types

  • Practice Guideline

MeSH terms

  • Administration, Cutaneous
  • Administration, Oral
  • Adrenal Cortex Hormones / administration & dosage
  • Antioxidants / therapeutic use
  • Calcineurin Inhibitors
  • Checklist
  • Combined Modality Therapy
  • Dermatologic Agents / therapeutic use
  • Humans
  • Immunosuppressive Agents / therapeutic use
  • Phototherapy / methods
  • Skin Lightening Preparations / therapeutic use
  • Steroids / administration & dosage
  • Treatment Outcome
  • Vitiligo / diagnosis
  • Vitiligo / therapy*


  • Adrenal Cortex Hormones
  • Antioxidants
  • Calcineurin Inhibitors
  • Dermatologic Agents
  • Immunosuppressive Agents
  • Skin Lightening Preparations
  • Steroids